Cold Agglutinin Disease Foundation
KZR-616, which is the investigational drug in this study, is a selective immunoproteasome inhibitor. The immunoproteasome is found inside cells of the immune system and is responsible for breaking down various proteins in these cells. By blocking protein breakdown, laboratory research has indicated that KZR-616 can reduce the inflammation and autoimmune processes that underly diseases like LN. We believe that KZR-616 may have broad therapeutic potential across multiple autoimmune diseases, while having the potential to avoid immunosuppression.
To be considered eligible for the MISSION study participants must:
Participants must meet other study criteria to take part in the MISSION Study.
Certain links within this site connect to other websites maintained by third parties over whom CADF has no control. CADF makes no representations as to the accuracy or any other aspect of information contained in other websites.
Providing these links does not imply any endorsement, non-endorsement, support or commercial gain by CADF.